RxDoctor Payments Data

Karen Hinton

Psychiatric/Mental Health · Madison, ALNPI 1659970515

Payments from drug & device makers

$3,870in general payments, 2019–2025

Across 142 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$544
  • Axsome Therapeutics, Inc.$494
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$472
  • Corium, LLC$452
  • Johnson & Johnson$416
  • Alkermes, Inc.$394
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,870 in reported general payments places this provider in the 75th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$27,226
Medicare patients
64
Services billed
363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl45$79,822
Invega SustennaPaliperidone Palmitate21$47,483
TrintellixVortioxetine Hydrobromide12$9,219
Lurasidone Hcl60$3,683
Duloxetine Hcl74$2,036
Desvenlafaxine Succinate ErDesvenlafaxine Succinate28$2,028
Buspirone Hcl79$1,899
Bupropion XlBupropion Hcl84$1,822
Aripiprazole59$1,698
Oxcarbazepine40$1,694
Quetiapine Fumarate119$1,628
Trazodone Hcl121$1,058
Lamotrigine55$899
Doxepin Hcl22$870
Hydroxyzine Hcl49$836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$212$79,82245 claims
Johnson & JohnsonInvega Sustenna$416$47,48321 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$256$9,21912 claims
Almatica Pharma LLCSertraline Hcl$59$52388 claims
Teva Pharmaceuticals USA, Inc.Loxapine$256$18111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →